Cancer testis antigens in sarcoma: Expression, function and immunotherapeutic application. (1st June 2020)

• Record Type: Journal Article
• Authors: Wei, Ran; Dean, Dylan C.; Thanindratarn, Pichaya; Hornicek, Francis J.; Guo, Wei; Duan, Zhenfeng
• Is Part Of: Cancer letters. Volume 479(2020)
• Page Start: 54
• Page End: 60
• Publication Date: 2020-06-01
• Subjects: Cancer testis antigen -- Sarcoma -- Expression -- Function -- Immunotherapy; Cancer -- Periodicals; Neoplasms -- Periodicals; Cancer -- Périodiques; Electronic journals; 616.994
• DOI: 10.1016/j.canlet.2019.10.024
• Languages: English
• ISSNs: 0304-3835

Abstract

Abstract: Sarcomas are a group of heterogeneous malignancies of mesenchymal origin. Patient outcomes remain especially grim for those with recurrent or metastatic disease, and current therapeutic strategies have not significantly improved outcomes over the past few decades. This has led to a number of studies assessing novel therapies. Cancer testis antigens (CTAs) are tumor-associated antigens with physiologic expression in the testis and various malignancies, including sarcomas. Genes encoding CTAs include MAGE, NY-ESO-1, PRAME, TRAG-3/CSAGE, and SSX. The importance and function of CTAs in tumorigenesis have gained recognition in recent years. They are also proving as robust diagnostic and prognostic biomarkers. Therapeutically, antigens derived from CTAs are highly recognizable by T lymphocytes and therefore capable of generating a potent antitumor immune response. CTAs are, therefore, promising targets for novel immunotherapies. Here we review the emerging works on expression, function, and immunotherapeutic application of CTAs in sarcoma therapy. Highlights: Cancer testis antigens (CTAs) are commonly expressed in sarcomas. Expression of CTAs is proving as robust diagnostic and prognostic biomarkers. CTAs are promising targets for novel sarcoma immunotherapies.